Sign In
Buy ZVSA
$0.170
-0.0002 (-0.118%)
At Close: Jun 02, 2026
Phase 2a trial is on track to begin in the first half of 2024. Cholesterol Efflux Mediator TM VAR 200 is in development to ameliorate renal lipid accumulation that damages the kidneys' filtration syst
Mr. Glover will talk about inflammasomes, and how they trigger development and spread of damaging inflammation, the culprit behind many deadly diseases.
WESTON, Fla., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for th
In obesity, inflammasome activation in fat tissue triggers cell death and release of inflammatory cytokines & ASC Specks, spreading damaging inflammation.
Should You Sell Your Penny Stocks? 3 Tips for When to Sell
06:12am, Tuesday, 27'th Feb 2024
Investing in penny stocks offers a unique opportunity for investors looking to expand their portfolios with potentially high-reward options. Recognized for their affordability, these stocks allow indi
Why Is ZyVersa Therapeutics (ZVSA) Stock Up 37% Today?
07:55am, Monday, 26'th Feb 2024
ZyVersa Therapeutics (NASDAQ: ZVSA ) stock is rocketing higher on Monday alongside heavy pre-market trading of the clinical-stage biopharmaceutical company's shares. ZVA stock is seeing a lot of acti
Neurological diseases, which affect up to 16 million people over 18 years old in the US, are the leading cause of physical and cognitive disability. A growing body of evidence supports that activation
ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases
07:53am, Wednesday, 14'th Feb 2024
Inflammation resulting from activation of more than one type inflammasome and ASC specks contribute to development and progression of neurological disease
ZyVersa CEO will discuss development milestones for Cholesterol Efflux Mediator VAR 200 and Inflammasome ASC Inhibitor IC 100 at BIO CEO & Investor Conf.
NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications (e.g., Type 2 Diabetes, Hypertension, Heart Disease).
Research demonstrated that activation of the inflammasome/ASC speck pathway has a vital role in synaptic degeneration in Alzheimer's Disease (AD). ZyVersa is developing IC 100, a monoclonal antibody t
ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis
07:52am, Wednesday, 17'th Jan 2024
Up to 40% of women with triple negative breast cancer (TNBC) experience metastasis to their brain, which affects physical function, independence, personality, quality of life, and significantly increa
ZyVersa Therapeutics' CEO, Stephen C. Glover, Featured on Benzinga All Access
08:06am, Wednesday, 10'th Jan 2024
WESTON, Fla., Jan. 10, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treat
ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets
07:50am, Thursday, 04'th Jan 2024
WESTON, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treat
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024
08:07am, Wednesday, 03'rd Jan 2024
WESTON, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treat
